Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Deferring Lesions by FFR in ACS: Yes or No?

Deferring Lesions by FFR in ACSDeferring treatment through angioplasty in non-ischemic lesions by fractional flow reserve (FFR) is associated with excellent long-term prognosis in patients with chronic ischemic heart disease.

 

FFR is beginning to be used for clinical decision-making in patients with acute coronary syndromes, and its long-term effect on stable chronic patients has not been established.

 

This study tries to determine the safety of deferring non-significant lesions by FFR in patients with acute coronary syndromes. For that purpose, the study included 206 consecutive patients with 262 intermediate lesions admitted for acute coronary syndrome and 370 patients with 528 intermediate lesions admitted for stable chronic angina in whom angioplasty was deferred on the basis of a FFR without evidence of myocardial ischemia (>0.75).

 

The primary endpoint was a composite of acute myocardial infarction and target vessel failure (major adverse cardiovascular events [MACE]).

 

In the entire cohort, in the long-term (3.4 ± 1.6 years), the rate of combined events was higher in the group with acute coronary syndrome than in the stable chronic group (23% vs. 11%, p <0.0001).

 

After a propensity score analysis that matched 200 patients in each group, the combined events rate is significantly higher for those with acute coronary syndrome (25% vs. 12%; p <0.0001).

 

Acute coronary syndrome patients presented a hazard ratio of 2.8 compared to stable patients (95% confidence interval [CI]: 1.9 to 4.0; p <0.0001).

 

In both the matched and unmatched cohorts, and across all FFR categories, patients with acute coronary syndrome presented higher rates of myocardial infarction and target vessel revascularization compared with stable patients (p <0.05).

 

In this study, the best FFR cutoff was <0.84 for patients with acute coronary syndrome (MACE 21% vs. 36%; p = 0.007) and <0.81 for stable patients (MACE 17% vs. 9%; p = 0.01).

 

Conclusion

Deferring coronary angioplasty on the basis of non-ischemic FFR in patients presenting acute coronary syndrome is significantly associated with worse outcomes when compared to stable chronic patients.

 

This study warns about risks derived from using FFR for clinical decision-making in acute patients.

 

Original title: Long-Term Prognosis of Deferred Acute Coronary Syndrome Lesions Based on Nonischemic Fractional Flow Reserve.

Reference: Abdul Hakeem et al. J Am Coll Cardiol. 2016;68(11):1181-1191.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...